Reserpine Clinical Trials

Size	Price	Qty
50mg	USD 147
1g	USD 670

Clinical Trials

Multiple Phase 1 through Phase 3 clinical trials, sponsored primarily by federal institutes and academic centers, evaluate reserpine for indications including cardiovascular, pulmonary, and substance-related disorders, as well as traumatic brain injury. Key research encompasses Phase 3 studies on geriatric hypertension management alongside Phase 2 trials addressing refractory hypertension and cocaine dependence. Overall trial statuses range from completed to withdrawn or terminated.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT06199778	TERMINATED	Traumatic Brain Injury	Zeng Changhao	2022-06-01
NCT03223272	COMPLETED	Refractory Hypertension	University of Alabama at Birmingham	2015-07-23	PHASE2
NCT02684786	WITHDRAWN	Pulmonary Artery Hypertension	Mayo Clinic	2016-07	PHASE1
NCT00000499	COMPLETED	Cardiovascular Diseases; Heart Diseases; Hypertension; Vascular Diseases	National Heart, Lung, and Blood Institute (NHLBI)	1980-09	PHASE2
NCT00000514	COMPLETED	Cardiovascular Diseases; Cerebrovascular Disorders; Heart Diseases; Hypertension	National Heart, Lung, and Blood Institute (NHLBI)	1984-06	PHASE3
NCT00267657	UNKNOWN	Amphetamine-Related Disorders	National Institute on Drug Abuse (NIDA)	2004-01	PHASE1
NCT00033033	COMPLETED	Cocaine-Related Disorders; Substance-Related Disorders	National Institute on Drug Abuse (NIDA)	2001-07	PHASE2

(data from https://clinicaltrials.gov, updated on 2024-03-05)

Check the Reserpine product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Reserpine selectively inhibits vesicular monoamine transporter 2 (VMAT2), preventing the sequestration of dopamine, norepinephrine, and serotonin into presynaptic vesicles and leading to their metabolic degradation by monoamine oxidase. This depletion of central and peripheral monoamine neurotransmitters reduces vascular tone and dampens neuronal signaling, underlying its clinical relevance in managing hypertension and substance dependence.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).